Drug
Autogene Cevumeran
Autogene Cevumeran: highest development phase Phase 2, developed by Roche. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Autogene Cevumeran NCT06534983 | Phase 2 | Muscle-invasive Urothelial Carcinoma |
Latest
No recent events.
Follow Autogene Cevumeran on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.